All In Biotech

NDA 203629 · Fresenius Kabi USA

Neostigmine Methylsulfate

Neostigmine Methylsulfate · Intravenous

Last checked: Nov 20, 2026Latest source record: Feb 4, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Jan 8, 2015

Approved uses

1

Original approval plus efficacy supplements

Registered trials

231

33 Phase 3, 11 recruiting

FAERS reports

365

331 serious, 53 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 15, 2024.

Neostigmine Methylsulfate Injection, a cholinesterase inhibitor, is indicated for reversal of the effects of nondepolarizing neuromuscular blocking agents (NMBA) after surgery. Neostigmine Methylsulfate, a cholinesterase inhibitor, is indicated for reversal of the effects of nondepolarizing neuromuscular blocking agents (NMBA) after surgery ( 1 ).

Mechanism: Neostigmine methylsulfate is a competitive cholinesterase inhibitor. By reducing the breakdown of acetylcholine, neostigmine methylsulfate induces an increase in acetylcholine in the synaptic cleft which competes for the same binding site as nondepolarizing neuromuscular blocking agents, and reverses the neuromuscular blockade.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • NEOSTIGMINE METHYLSULFATE · NEOSTIGMINE METHYLSULFATE 3MG/3ML (1MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
  • NEOSTIGMINE METHYLSULFATE · NEOSTIGMINE METHYLSULFATE 5MG/10ML (0.5MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • NEOSTIGMINE METHYLSULFATE · NEOSTIGMINE METHYLSULFATE 10MG/10ML (1MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Neostigmine Methylsulfate" as an intervention, any sponsor and status, largest first.

All 231 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective34
  • abdominal distension25
  • nausea23
  • hypotension22
  • respiratory failure20
  • abdominal pain19
  • white blood cell count increased18
  • cardiac arrest16
  • pyrexia16
  • bradycardia15
  • generalised tonic-clonic seizure15
  • subileus15

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20055
20066
20073
20084
20096
20105
20113
201216
20139
201416
201511
201623
201719
201825
201926
202020
202120
202229
202334
202445
202529
202611

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Jan 12, 2026

    Neostigmine Methylsulfate, Injection, .5 mg/1 mL (NDC 63323-413-10). Discontinuation of the manufacture of the drug

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 5 on PubMed

Sponsor: Fresenius Kabi USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.